SPOTLIGHT -
Unveiling Practice-Changing Data in CLL, GVHD, and MPNs: Drs Catherine Coombs, Nelli Bejanyan, and Aaron Gerds
Read More
Dr. Gerds on the VERIFY Trial Examining Rusfertide in Polycythemia Vera
Aaron T. Gerds, MD, MS, discusses the phase 3 VERIFY trial examining rusfertide in patients with polycythemia vera.
Dr. Gerds on Emerging Agents in Myelofibrosis
Aaron T. Gerds, MD, MS, discusses emerging agents in myelofibrosis.
Dr. Gerds on the Rationale for the Real-World REVEAL Study in Polycythemia Vera
Aaron T. Gerds, MD, MS, discusses the rationale for the real-world REVEAL study in polycythemia vera.
PERSIST-1 and PERSIST-2 Trials in Myelofibrosis
Expert hematologist/oncologists review the use of pacritinib for the treatment of myelofibrosis, as seen in the PERSIST-1 and PERSIST-2 trials.
Role of JAK-STAT Pathway in Myelofibrosis
Aaron Gerds, MD, MS; and Srdan Verstovsek, MD, PhD, share insights on the impact of pathways, including JAK-STAT, on myelofibrosis disease progression and discuss considerations for the use of JAK inhibitors.
Monitoring Treatment Response in MF
Hematology/oncology experts review their approach to monitoring treatment response in myelofibrosis (MF) and when they would consider switching therapies.
Impact of Cytopenias on MF Treatment
Aaron Gerds, MD, MS; and Srdan Verstovsek, MD, PhD, share insights on the importance of allele burden in myelofibrosis (MF) and how cytopenias can limit treatment options for patients with myelofibrosis.
Challenges in Myelofibrosis Treatment
Experts in hematology/oncology comment on challenges in treating patients with myelofibrosis.
Treatment Strategies for Primary Myelofibrosis
Srdan Verstovsek, MD, PhD, and Aaron Gerds, MD, MS, review key updates to NCCN guidelines for primary myelofibrosis and discuss treatment options for the disease.
Risk Stratification and Patient Classification for PMF
Aaron Gerds, MD, MS, provides insight on determining low- vs high-risk primary myelofibrosis, the role of molecular status on treatment, and his approach toward symptom burden assessment.
Overview of Primary Myelofibrosis
Srdan Verstovsek, MD, PhD, describes the classic signs and symptoms of primary myelofibrosis (PMF), along with goals of therapy.
Second-Line Treatment of R/R LBCL With Lisocabtagene Maraleucel (Liso-cel)
ZUMA-7: Axicabtagene Ciloleucel as a Second-Line Therapy for LBCL
Currently Available Treatment Options for Patients With R/R DLBCL
Overview of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)